RDHL RedHill Biopharma Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1553846
Financial factors as of 2021-12-31 (FY2021), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2022Q2*2022-06-30 | 2021Q2*2021-06-30 | 2020Q2*2020-06-30 | 2019Q2*2019-06-30 | 2018Q2*2018-06-30 | 2017Q2*2017-06-30 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $18.35M | $21.50M | $20.90M | $1.56M | $2.35M | $483,000 |
| Cost of revenue | $8.99M | $10.59M | $14.19M | $425,000 | $725,000 | $272,000 |
| Gross profit | $9.35M | $10.91M | $6.71M | $1.14M | $1.62M | $211,000 |
| R&D expense | $1.47M | $10.33M | $3.21M | $6.97M | $6.04M | $8.43M |
| SG&A expense | $7.76M | $10.23M | $6.03M | $2.40M | $2.02M | $1.94M |
| Operating income | -$9.16M | -$24.89M | -$12.50M | -$12.38M | -$9.56M | -$13.54M |
| Interest expense | $4.21M | $4.25M | $3.65M | $74,000 | $1.72M | $7,000 |
| Net income | -$11.71M | -$29.12M | -$16.05M | -$10.91M | -$11.12M | -$11.02M |
| EPS (basic) | -0.02 | -0.06 | 0.04 | 0.04 | 0.05 | 0.06 |
| EPS (diluted) | -0.02 | -0.06 | 0.04 | 0.04 | 0.05 | 0.06 |
| Balance sheet | ||||||
| Cash & equivalents | $26.99M | $51.82M | $22.27M | $8.99M | $5.56M | $15.32M |
| Receivables | $33.76M | $30.10M | $18.57M | $963,000 | $1.80M | — |
| Inventory | $11.72M | $8.76M | $4.75M | $1.83M | $690,000 | — |
| Current assets | $91.27M | $98.49M | $61.13M | $39.97M | $32.22M | — |
| PP&E, netmay include right-of-use assets (IFRS) | $616,000 | $506,000 | $345,000 | $250,000 | $200,000 | — |
| Intangibles | $68.74M | $84.22M | $79.52M | $5.32M | $5.29M | — |
| Total assets | $167.97M | $203.67M | $166.37M | $49.70M | $37.85M | — |
| Current liabilities | $166.41M | $79.17M | $35.87M | $14.05M | $9.88M | — |
| Short-term debt | $85.51M | — | — | — | — | — |
| Long-term debt | — | $83.16M | $79.19M | — | — | — |
| Total debt | — | $83.16M | $79.19M | — | — | — |
| Total liabilities | $179.91M | $174.09M | $131.78M | $17.79M | $11.94M | — |
| Shareholders' equity | -$11.94M | $29.58M | $34.59M | $31.90M | $25.91M | $48.80M |
| Net debt | — | $31.34M | $56.92M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | -$16.58M | -$18.90M | -$15.03M | -$10.45M | -$8.40M | -$9.73M |
| Capital expenditure | $163,000 | $3,000 | $20,000 | $128,000 | $2,000 | $102,000 |
| Free cash flow | -$16.74M | -$18.90M | -$15.05M | -$10.58M | -$8.40M | -$9.83M |
| Investing cash flow | -$163,000 | -$3.50M | -$49.80M | -$3.39M | $6.46M | -$4.87M |
| Financing cash flow | $14.92M | -$1.77M | $5.46M | -$199,000 | — | $175,000 |
| Stock-based compensation | $618,000 | $5.27M | $623,000 | $937,000 | $733,000 | $705,000 |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.